Privilège Ventures SA is a seed and early stage venture capital firm. We take an active, hands-on approach that leverages our entrepreneurial expertise. We partner with entrepreneurs to create a sustainable and scalable business. We proudly launched our CEO Scouting Program involving some of the best entrepreneurs we met over the years.
Location: Switzerland, Ticino, Lugano
Employees: 1-10
Founded date: 2021
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| 03.03.2026 | Xsensio | xsensio.com | $11.59M | Switzerlan... |
| 15.07.2022 | Wyth™ | wyth.live | $1.63M | Switzerlan... |
| 18.01.2022 | INERGIO | inergio.ch | $1.37M | Switzerlan... |
Mentions in press and media 28
| Date | Title | Description |
| 05.03.2026 | Xsensio Secures $7M to Propel Real-Time Wearable Biosensing into Clinical Practice | Xsensio secured $7M Series A funding. This investment propels its innovative "Lab-on-Skin" wearable biosensing platform forward. The system delivers continuous, real-time biochemical data directly from the body. It monitors crucia... |
| 03.03.2026 | Xsensio: $7 Million Raised In Series A To Advance Continuous Biochemical Monitoring Platform | Xsensio SA, a Swiss deep-tech company focused on near-real-time continuous biochemical monitoring, announced the closing of a $7 million oversubscribed Series A financing round to accelerate the clinical deployment of its wearable biosensin... |
| 03.03.2026 | Xsensio’s wearable chip that analyses proteins and hormones in real time draws €6 million | Xsensio, a Lausanne-based DeepTech company developing near real-time continuous biochemical monitoring, announced the successful closing of a €6 million ($7 million) oversubscribed Series A financing round. The round was led by VC firm WI H... |
| 02.03.2026 | Oversubscribed $7M Series A to boost Xsensio biosensing clinical deployment | Xsensio develops the Lab-on-Skin wearable biosensing platform to deliver continuous, real-time biochemical information for personalized and preventive healthcare. Designed for multiparametric analysis, its ultra-miniaturized chip integrate... |
| 27.06.2024 | CHF1.8 million to eliminate critical bottlenecks in traditional drug development | ENANTIOS technology, developed over a five-year research project at ETH Zurich, enables the complete characterization of complex molecules and aspects of the three dimensional structure which are not possible to resolve with other methods.... |
| 01.03.2023 | Interview with Aike Festini: Integrity, authenticity, and the lessons learned from failure | Interview with Aike Festini: Integrity, authenticity, and the lessons learned from failure 01.03.2023 06:00, Morgane Ghilardi linkedIn facebook twitter instagram youtube --> Statistically, a startup is much more likely to fold than to su... |
| 06.01.2023 | Privilège Ventures Launches Fund for Female Led Startups | The Swiss-based venture capital firm will invest in female founders with its CHF 20 million Fund IV; “We don’t just want to support women,” said Privilège’s Jacqueline Ruedin Rüsch. “The data shows women in the driver’s seat produce better ... |
| 07.11.2022 | Privilège Ventures Launches Fund for Female Led Startups | Privilège Ventures, a Lugano, Switzerland-based venture capital firm, launched CHF 20m Fund IV, dedicated to scouting and investing in female led early-stage startups across Europe. Fund IV will seek 15-20 seed and early-stage female led co... |
| 03.11.2022 | Privilège Ventures launches fund for female led startups | |
| 03.11.2022 | Privilège Ventures launches $20M fund investing in women-led startups | Lugano, Switzerland-based venture capital fund Privilège Ventures just launched its fourth fund. The CHF 20 million (just over $20 million) fund is earmarked for women-led early-stage startups across Europe. “We don’t just want to support w... |
Show more